Evidence map›Paper›PMID 25483452›Full record

ReviewCA: a cancer journal for clinicians2015

Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults.

Jeffrey S Wefel, Shelli R Kesler, Kyle R Noll, Sanne B Schagen

Registry-linked trialOpen access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in CA: a cancer journal for clinicians, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05333250 (Modafinil to Improve Fatiguability), which is not on this map. Cited by 296 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
296citing papers in PubMed, 12 pooled it
22.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05333250 phase1 / phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Modafinil to Improve Fatiguability (MODIFY): Modafinil vs. Placebo Vanguard RCT

TypeinterventionalSponsorOttawa Hospital Research InstituteRan2026 to 2028Enrolled40ConditionsCancer-related Cognitive Difficulties, Cancer-related Problem/Condition, FatigueArmsModafinil, Placebo
3 · Its place in the literature

Who cites it

296 citing papers in PubMed, 12 syntheses or guidelines pooled it, 532 citations in OpenAlex.

  1. A comprehensive review of European clinical practice guidelines on psychological and cognitive assessment and support for cancer patients and their families.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Cancer-related cognitive impairment in patients with hematologic malignancies after CAR T cell therapy: a systematic review and meta-analysis of prevalence.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Guideline
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

236 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Jeffrey S WefelAssociate Professor, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Shelli R Kesler
Kyle R Noll
Sanne B Schagen
The University of Texas MD Anderson Cancer Center · USThe Netherlands Cancer Institute · NL

Funding

Very-long Term Neurocognitive Outcomes in Breast Cancer Survivors (ProbC2)R01CA172145 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI KESLER, SHELLI R, PALESH, OXANA G · 2012 to 2024
$3.3M
Multimodal MRI Biomarker of Mild Cognitive Impairment in Breast CancerR01NR014195 · NINR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KESLER, SHELLI R, WEFEL, JEFFREY SCOTT · 2012 to 2017
$2.5M
NCI NIH HHS R01 CA172145NCI NIH HHS R01CA172145NINR NIH HHS R01 NR014195NINR NIH HHS R01NR014195
6 · The paper itself

Abstract

Answer questions and earn CME/CNE Over the past few decades, a body of research has emerged confirming what many adult patients with noncentral nervous system cancer have long reported-that cancer and its treatment are frequently associated with cancer-related cognitive impairment (CRCI). The severity of CRCI varies, and symptoms can emerge early or late in the disease course. Nonetheless, CRCI is typically mild to moderate in nature and primarily involves the domains of memory, attention, executive functioning, and processing speed. Animal models and novel neuroimaging techniques have begun to unravel the pathophysiologic mechanisms underlying CRCI, including the role of inflammatory cascades, direct neurotoxic effects, damage to progenitor cells, white matter abnormalities, and reduced functional connectivity, among others. Given the paucity of research on CRCI with other cancer populations, this review synthesizes the current literature with a deliberate focus on CRCI within the context of breast cancer. A hypothetical case-study approach is used to illustrate how CRCI often presents clinically and how current science can inform practice. While the literature regarding intervention for CRCI is nascent, behavioral and pharmacologic approaches are discussed.

Indexed as

AdultAnimalsAntineoplastic AgentsBreast NeoplasmsCognitive Behavioral TherapyCognitive DysfunctionEvidence-Based MedicineFemaleHumansMemory DisordersRadiotherapy, AdjuvantSeverity of Illness IndexTreatment OutcomeAntineoplastic Agentsbreast neoplasmschemotherapycomplications and late effects of therapypsychological/behavioral oncology

Identifiers

PMID25483452
PMCPMC4355212
OpenAlexW2112382743

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.